TMA/TI/Diuretics/Cyst Flashcards
thrombocytopenia, hemolytic anemia and dysfunction of affected organs
Thrombotic microangiopathy
renal dominant disease
hemolytic uremic syndrome
Predominant neurological involvement
ttp
severe adamts13 deficienct
ttp
most sensitive marker of hemopysis due to cell lysis and tissue ischemia
elevated ldh
pathological features of tma - blood
schistocytes
glomerular capillary wall thickening with thrombi
Acute hus
initial treatment of choice in TTP
Plasma exchange
recombinized humanized monoclonal antibody that functionally blocks C5, 1st line treatment for children
Eculizumab
predominant pathogen in stec-hus
E coli 0157
classical prodromal feature of stec-hus
Bloody diarrhea
Principal effector mediating tubulointerstitial fibrosis
fibroblasts
final common pathway leading to eskd
Fibrosis
abrupt deterioration in renal function and characterized by inflammation and edema in the renal interstitium
Acute interstitial nephritis
1/3 of cases of drug related ain are caused by
antibiotics
pathology of infection causing ain
Direct injury
medications used
hallmark pathology of ain
Infiltration of inflammatory cells with associated edema usually sparing glomeruli and blood vessels
epithelial cell degenration resembling patchy tubular necrosis with some disruption of the tbm
Tubulitis
dress syndrome
drug rash
eosinophilia
systemic symptoms
40% of drug induced ain
rising serum crea level but little or no evidence of glomerular or arterial disease, no prerenal factors, no obstruction + clinical hx of exposure to a high risk drug
ain
provide confirmatory evidence of AIN
Urine eosinophils
gold standard dx of ain
Renal biopsy
lymphocytic infiltrates in the peritubular areas of the interstitium usually with edema
ain
management of ain
withdrawal of factor, supportive care
time when medication should be discontinued that recovery is expected
within 2 weeks
dose of steroids in ain
prednisone 1mkd po for 2-3 weeks followed by tapering over 3-4 weeks
given to patients who fail to respond to a 2 week course of steroid therapy in ain
cyclophosphamide 4 week 2mkd
immunosuppresive agent used in granulomatosis interstitial nephritis
Mycophenopate mofetil
used in patients with circulating anti-tbm and anti-gbm antibodies
Plasmapharesis
worse prognosis in ain
increasing ageb
biopsy of diffuse disease + interstitial fibrosis
amount of analgesic to vayse analgesic nephropathy
6 tablets daily for > 3 years
decreased renal size, bumpy contours and papillary calcification
analgesic nephropathy
identified risk factor in lithium for ain
Duration of therapy
most powerful predictor of ultimate progression to eskd in lithium as cause of ain
> 2.5 mg/dL
Tx for lead nephropathy
Chronic edta chelation